🇺🇸 Silymarin (Silybum marianum) in United States

27 US adverse-event reports

Safety signals — FAERS

Adverse reaction reports describe suspected side effects. A report does not mean the drug caused the event — co-medications, underlying disease and coincidence all contribute.

• Window: 22 April 2025 – 22 April 2026
• Total reports: 27

Most-reported reactions

1. Pyrexia — 6 reports (22.22%)
2. Decreased Appetite — 3 reports (11.11%)
3. Dyspnoea — 3 reports (11.11%)
4. Platelet Count Decreased — 3 reports (11.11%)
5. Anaemia — 2 reports (7.41%)
6. Aspartate Aminotransferase Increased — 2 reports (7.41%)
7. Chills — 2 reports (7.41%)
8. Diabetes Mellitus — 2 reports (7.41%)
9. Drug Ineffective — 2 reports (7.41%)
10. Fatigue — 2 reports (7.41%)

Source database →

Frequently asked questions

Is Silymarin (Silybum marianum) approved in United States?

Silymarin (Silybum marianum) does not currently have US marketing authorisation in our dataset.

Who is the marketing authorisation holder for Silymarin (Silybum marianum) in United States?

University of Maryland, Baltimore is the originator. The local marketing authorisation holder may differ — check the official source linked above.